US Patent 8048899 Compounds which selectively modulate the CB2 receptor
Patent 8048899 was granted and assigned to Boehringer Ingelheim on November, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+265 characters)
Article
Patent abstract
are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+15 properties)
Infobox
Patent Inventor Names
Achim Sauer0
Alessandra Bartolozzi0
Angela Berry0
David Smith Thomson0
Doris Riether0
Eugene Richard Hickey0
Innocent Mushi0
Lifen Wu0
Markus Ostermeier0
Monika Ermann0
Nigel James Blumire0
Patricia Amouzegh0
Renee M. Zindell0
Someina Khor0
Stephen Peter East0
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08048899 Compounds which selectively modulate the CB2 receptor US Patent 8048899 Compounds which selectively modulate the CB2 receptor
Infobox
Patent Number
08048899
Patent Number
8048899
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08048899 Compounds which selectively modulate the CB2 receptor
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08048899
Date of patent
November 1, 2011
Patent application number
12564132
Date Filed
September 22, 2009
Patent primary examiner
Find more entities like US Patent 8048899 Compounds which selectively modulate the CB2 receptor
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
